ADAMTS5 is considered as an anti-target in CHD (reviewed in Santamaria 2020 (ref. 31)), since recombinant ADAMT5 has been shown to release low density lipoproteins (LDLs) from human atherosclerotic lesions and ApoE−/− knockout mice have higher levels of ADAMTS5 and its proteoglycan (proatherogenic) substrates.32 Here, we report the design and synthesis of a series of novel hydroxamate-based arylsulfonamides which represent a first step towards obtaining selective ADAMTS7 inhibitors. Here, ADAMTS7 is linked to coronary artery disorder.